Wave Life Sciences

Wave Life Sciences is a clinical-stage biotechnology company founded in 2012 through the merger of two smaller firms, Ontorii in Boston and Chiralgen in Japan. It was established by scientific leaders Gregory Verdine, a professor at Harvard University, and Takeshi Wada, a professor at Tokyo University of Science. The company is incorporated in Singapore, with its main U.S. headquarters and research and development activities in Cambridge, Massachusetts. A significant milestone was its initial public offering on November 11, 2015, trading on NASDAQ under the ticker WVE.

The company's business model is characteristic of the biotechnology sector, focusing heavily on research and development and relying on its intellectual property. Revenue is primarily generated through strategic partnerships and licensing agreements rather than direct product sales. A notable collaboration is with GSK, which involved a $170 million upfront payment and could total over $3.3 billion, for the development of up to eight oligonucleotide therapeutic programs. This partnership model allows Wave to fund its extensive R&D while leveraging the genomic expertise of larger pharmaceutical companies. As of June 2025, the company reported having $208.5 million in cash and equivalents, providing a financial runway into 2027.

Wave Life Sciences specializes in developing stereopure nucleic acid therapeutics to treat genetically defined diseases. The core of its operations is the proprietary PRISM® platform, a discovery and drug development engine that designs stereopure oligonucleotides with precisely controlled molecular structures. This platform integrates multiple therapeutic modalities, including RNA interference (RNAi), antisense silencing, splicing, and RNA editing. A key component of this is their AIMers (A-to-I RNA base editing oligonucleotides) technology, which recruits the body's own ADAR enzymes to correct RNA mutations without altering the underlying DNA. The company's diversified pipeline includes clinical programs for rare diseases like Alpha-1 antitrypsin deficiency (AATD), Duchenne muscular dystrophy (DMD), and Huntington’s disease (HD), as well as more common conditions like obesity.

Keywords: RNA medicines, stereopure oligonucleotides, PRISM platform, genetic diseases, nucleic acid therapeutics, clinical-stage biotechnology, antisense, RNA editing, RNA interference, Alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, Huntington’s disease, obesity treatment, AIMers, GSK collaboration, Paul Bolno, Gregory Verdine, Takeshi Wada, allele-selective, oligonucleotide chemistry